Can we vaccinate against atherosclerosis?

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 1, 2014, Pages 77-82

  Chyu, Kuang Yuh ^a   Shah, Prediman K ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

atherosclerosis; immunization; vaccine

Indexed keywords

ANTIGEN; APOLIPOPROTEIN B100; DNA VACCINE; IMMUNOGLOBULIN M ANTIBODY; IMMUNOMODULATING AGENT; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; VACCINE;

ACTIVE IMMUNIZATION; ATHEROGENESIS; ATHEROSCLEROSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG FORMULATION; HUMAN; HUMORAL IMMUNITY; HYPERCHOLESTEROLEMIA; IMMUNOMODULATION; KNOWLEDGE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ATHEROSCLEROSIS; IMMUNIZATION; VACCINE;

ANIMALS; ATHEROSCLEROSIS; HUMANS; IMMUNE SYSTEM; IMMUNIZATION, PASSIVE; VACCINATION; VACCINES;

EID: 84890917105     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413498822     Document Type: Review

References (50)

1. Gero S, Gergely J, Jakab L, et al. Inhibition of cholesterol atherosclerosis by immunisation with beta-lipoprotein. Lancet. 1959 ; 2 (7088). 6-7
2. Plotkin SA. Vaccines: past, present and future. Nat Med. 2005 ; 11 (4 suppl). S5 - S11
3. Plotkin SA. Six revolutions in vaccinology. Pediatr Infect Dis J. 2005 ; 24 (1). 1-9
4. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA. 1995 ; 92 (3). 821-825
5. Ameli S, Hultgardh-Nilsson A, Regnstrom J, et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol. 1996 ; 16 (8). 1074-1079
6. Nilsson J, Calara F, Regnstrom J, et al. Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits. J Am Coll Cardiol. 1997 ; 30 (7). 1886-1891
7. Alving CR, Swartz GM, Wassef NM, et al. Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation. J Lab Clin Med. 1996 ; 127 (1). 40-49
8. George J, Afek A, Gilburd B, et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis. 1998 ; 138 (1). 147-152
9. Zhou X, Caligiuri G, Hamsten A, Lefvert AK, Hansson GK. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol. 2001 ; 21 (1). 108-114
10. Fredrikson GN, Hedblad B, Berglund G, et al. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler Thromb Vasc Biol. 2003 ; 23 (5). 872-878
11. Fredrikson GN, Soderberg I, Lindholm M, et al. Inhibition of atherosclerosis in ApoE-null mice by immunization with ApoB-100 peptide sequences. Arterioscler Thromb Vasc Biol. 2003 ; 23 (5). 879-884
12. Chyu KY, Zhao X, Reyes OS, et al. Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-/-) mice. Biochem Biophys Res Commun. 2005 ; 338 (4). 1982-1989
13. Fredrikson GN, Bjorkbacka H, Soderberg I, Ljungcrantz I, Nilsson J. Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies. J Intern Med. 2008 ; 264 (6). 563-570
14. Klingenberg R, Lebens M, Hermansson A, et al. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler Thromb Vasc Biol. 2010 ; 30 (5). 946-952
15. Chyu KY, Zhao X, Dimayuga PC, et al. CD8+ T cells mediate the athero-protective effect of immunization with an ApoB-100 peptide. PLoS One. 2012 ; 7 (2). e30780
16. Wigren M, Kolbus D, Duner P, et al. Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine. J Intern Med. 2011 ; 269 (5). 546-556
17. Herbin O, Ait-Oufella H, Yu W, et al. Regulatory T-cell response to apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2012 ; 32 (3). 605-612
18. Pierides C, Bermudez-Fajardo A, Fredrikson GN, Nilsson J, Oviedo-Orta E. Immune responses elicited by apoB-100-derived peptides in mice. Immunol Res. 2013 ; 56 (1). 96-108
19. Horkko S, Bird DA, Miller E, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest. 1999 ; 103 (1). 117-128
20. Friedman P, Horkko S, Steinberg D, Witztum JL, Dennis EA. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol concentration. J Biol Chem. 2002 ; 277 (9). 7010-7020
21. Shaw PX, Horkko S, Chang MK, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest. 2000 ; 105 (12). 1731-1740
22. Chang MK, Bergmark C, Laurila A, et al. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci USA. 1999 ; 96 (11). 6353-6358
23. Briles DE, Forman C, Hudak S, Claflin JL. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med. 1982 ; 156 (4). 1177-1185
24. Yother J, Forman C, Gray BM, Briles DE. Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody. Infect Immun. 1982 ; 36 (1). 184-188
25. Binder CJ, Horkko S, Dewan A, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med. 2003 ; 9 (6). 736-743
26. Hermansson A, Ketelhuth DF, Strodthoff D, et al. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med. 2010 ; 207 (5). 1081-1093
27. Hauer AD, van Puijvelde GH, Peterse N, et al. Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2007 ; 27 (9). 2050-2057
28. van Wanrooij EJ, De Vos P, Bixel MG, Vestweber D, van Berkel TJ, Kuiper J. Vaccination against CD99 inhibits atherogenesis in low-density lipoprotein receptor-deficient mice. Cardiovasc Res. 2008 ; 78 (3). 590-596
29. Rittershaus CW, Miller DP, Thomas LJ, et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 2000 ; 20 (9). 2106-2112
30. Gaofu Q, Jun L, Xin Y, et al. Vaccinating rabbits with a cholesteryl ester transfer protein (CETP) B-cell epitope carried by heat shock protein-65 (HSP65) for inducing anti-CETP antibodies and reducing aortic lesions in vivo. J Cardiovasc Pharmacol. 2005 ; 45 (6). 591-598
31. Mao D, Kai G, Gaofu Q, et al. Intramuscular immunization with a DNA vaccine encoding a 26-amino acid CETP epitope displayed by HBc protein and containing CpG DNA inhibits atherosclerosis in a rabbit model of atherosclerosis. Vaccine. 2006 ; 24 (23). 4942-4950
32. Davidson MH, Maki K, Umporowicz D, Wheeler A, Rittershaus C, Ryan U. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis. 2003 ; 169 (1). 113-120
33. Kilic A, Mandal K. Heat shock proteins: pathogenic role in atherosclerosis and potential therapeutic implications. Autoimmune Dis. 2012;2012 ;:
34. Almanzar G, Ollinger R, Leuenberger J, et al. Autoreactive HSP60 epitope-specific T-cells in early human atherosclerotic lesions. J Autoimmun. 2012 ; 39 (4). 441-450
35. Grundtman C, Wick G. The autoimmune concept of atherosclerosis. Curr Opin Lipidol. 2011 ; 22 (5). 327-334
36. Grundtman C, Kreutmayer SB, Almanzar G, Wick MC, Wick G. Heat shock protein 60 and immune inflammatory responses in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011 ; 31 (5). 960-968
37. Xu Q, Dietrich H, Steiner HJ, et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb. 1992 ; 12 (7). 789-799
38. Zhang Y, Xiong Q, Hu X, et al. A novel atherogenic epitope from mycobacterium tuberculosis heat shock protein 65 enhances atherosclerosis in rabbit and LDL receptor-deficient mice. Heart Vessels. 2012 ; 27 (4). 411-418
39. George J, Shoenfeld Y, Afek A, et al. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler Thromb Vasc Biol. 1999 ; 19 (3). 505-510
40. Long J, Lin J, Yang X, et al. Nasal immunization with different forms of heat shock protein-65 reduced high-cholesterol-diet-driven rabbit atherosclerosis. Int Immunopharmacol. 2012 ; 13 (1). 82-87
41. Klingenberg R, Ketelhuth DF, Strodthoff D, Gregori S, Hansson GK. Subcutaneous immunization with heat shock protein-65 reduces atherosclerosis in ApoE-/- mice. Immunobiology. 2012 ; 217 (5). 540-547
42. Li J, Zhao X, Zhang S, Wang S, Du P, Qi G. ApoB-100 and HSP60 peptides exert a synergetic role in inhibiting early atherosclerosis in immunized ApoE-null mice. Protein Pept Lett. 2011 ; 18 (7). 733-740
43. Lu X, Chen D, Endresz V, et al. Immunization with a combination of ApoB and HSP60 epitopes significantly reduces early atherosclerotic lesion in Apobtm2SgyLdlrtm1Her/J mice. Atherosclerosis. 2010 ; 212 (2). 472-480
44. Chyu KY, Zhao X, Reyes OS, et al. Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-/-) mice. Biochem Biophys Res Commun. 2005 ; 338 (4). 1982-1989
45. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler Thromb. 1994 ; 14 (1). 141-147
46. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994 ; 14 (1). 133-140
47. Virella G, Lopes-Virella MF. Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis. 2008 ; 200 (2). 239-246
48. Lopes-Virella MF, Virella G. Clinical significance of the humoral immune response to modified LDL. Clin Immunol. 2010 ; 134 (1). 55-65
49. Paulsson G, Zhou X, Tornquist E, Hansson GK. Oligoclonal T cell expansions in atherosclerotic lesions of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2000 ; 20 (1). 10-17
50. Hansson GK, Jonasson L. The discovery of cellular immunity in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 2009 ; 29 (11). 1714-1717